The outcomes and costs of acute myeloid leukemia among the elderly

Archives of Internal Medicine

Volumn 162, Issue 14, 2002, Pages 1597-1603

  Menzin, Joseph ^a   Lang, Kathleen ^a   Earle, Craig C ^b   Kerney, Donna ^a   Mallick, Rajiv ^c  

^a Boston Health Economics Inc   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE DISEASE; AGING; ARTICLE; CIGARETTE SMOKING; DATA ANALYSIS; ELDERLY CARE; HEALTH CARE COST; HUMAN; INCIDENCE; MEDICARE; MYELOID LEUKEMIA; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSPECTIVE PAYMENT; RELIGION;

ACUTE DISEASE; AGE FACTORS; AGED; AGED, 80 AND OVER; COHORT STUDIES; DELIVERY OF HEALTH CARE; DRUG THERAPY; FEMALE; HUMANS; INCIDENCE; LEUKEMIA, MYELOID; MALE; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; UNITED STATES;

EID: 0037158110     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.162.14.1597     Document Type: Article

References (35)

1. Antibody-targeted chemotherapy for the treatment of relapsed acute myeloid leukemia
2. Acute myeloid leukemia
3. How I treat older patients with AML
4. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: A Southwest Oncology Group study
5. Validating the use of administrative claims data for assessing cancer relapse: The case of acute myeloid leukemia (AML)
6. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
7. Colony-stimulating factors in the treatment of older patients with acute myelogenous leukaemia
8. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis
9. Cost of care for cancer in a Health Maintenance Organization
10. Prognostic factors in clinical cancer trials
11. De novo acute myeloid leukemia in patients over 55-years-old a population-based study of incidence, treatment and outcome
12. GM-CSF, ARA-C, VP-16 and idarubicin (GM-IVA), a short, and effective induction treatment for de novo AML, suitable for the elderly
13. Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients (>50 to 70 years of age) with acute myelogenous leukemia
14. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study (9031)
15. Cost-effectiveness and quality of life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia
16. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy: The value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: Final report
17. Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in the treatment of patients with acute myeloid leukemia in first relapse
18. Efficacy and safety of Mylotar (gemtuzumab ozogamcin) in patients with CD22-positive acute myeloid leukemia in first relapse
19. A randomized, double-blind placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia
20. A phase II trial of induction and consolidation therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk elderly patients
21. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia
22. Access to palliative care and hospice in nursing homes
23. Assessing quality using administrative data
24. Representativeness of the surveillance, epidemiology, and end results program data: Recent trends in cancer mortality rates
25. Use of Medicare data to identify incident breast cancer cases
26. Underutilization of mammography in older breast cancer survivors
27. Stage at diagnosis and treatment patterns among older women with breast cancer: An HMO and fee-for-service comparison
28. Use of Medicare hospital and physician data to assess breast cancer incidence
29. Prostate cancer treatment and 10-year survival among group/staff HMO and FFS Medicare patients
30. Racial differences in the treatment of early-stage lung cancer
31. Estimating the costs attributable to a disease with application to ovarian cancer